Literature DB >> 20022309

Determination of free and liposomal amphotericin B in human plasma by liquid chromatography-mass spectroscopy with solid phase extraction and protein precipitation techniques.

Niranjan M Deshpande1, Manish G Gangrade, Maharudra B Kekare, Vikas V Vaidya.   

Abstract

Amphotericin B is available in various drug delivery systems such as cholesteryl sulfate complex, as lipid complex, and as liposomal formulation. The separation and measurement of free drug (drug which is not bound with liposomal lipids) and liposomal drug (drug which is entrapped in liposomes) in the human plasma after injection of liposomal Amphotericin B is of prime importance due to toxicity concerns. A robust, specific and sensitive method has been developed to effectively separate and then quantify the free drug and liposomal drug, present in human plasma. This method utilizes solid phase extraction Oasis HLB cartridges, which retains the free drug and the liposomal Amphotericin B was eluted from the cartridge in first step. The eluted liposomal Amphotericin B was then extracted from lipids by protein precipitation method using 2% dimethylsulfoxide (DMSO) in acetonitrile. After separation and extraction, the quantification of free and liposomal fractions of Amphotericin B was performed by HPLC-MS-MS technique. The chromatographic separation was performed using Chromolith Performance RP 18e column. The mobile phase composed of 5 mM ammonium acetate, methanol and acetonitrile and a gradient elution program was used. The calibration curves were found to be linear for free Amphotericin B (0.25-15.0 microg/ml) and liposomal Amphotericin B (1.0-100.0 microg/ml). The recovery was about 96% for free Amphotericin B and about 92% for liposomal Amphotericin B. Recoveries were consistent over the linearity ranges defined. The intra-batch and inter-batch accuracy and precision fulfilled the international requirements. The stability of free and liposomal Amphotericin B was assessed under different storage conditions. 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20022309     DOI: 10.1016/j.jchromb.2009.11.036

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  10 in total

1.  Noninvasive fluorescence resonance energy transfer imaging of in vivo premature drug release from polymeric nanoparticles.

Authors:  Peng Zou; Hongwei Chen; Hayley J Paholak; Duxin Sun
Journal:  Mol Pharm       Date:  2013-10-14       Impact factor: 4.939

2.  Determination of Liposomal Cisplatin by High-Performance Liquid Chromatography and Its Application in Pharmacokinetic Studies.

Authors:  Alfonso Toro-Córdova; Fabricio Ledezma-Gallegos; Laura Mondragon-Fuentes; Rafael Jurado; Luis A Medina; Jazmin M Pérez-Rojas; Patricia Garcia-Lopez
Journal:  J Chromatogr Sci       Date:  2016-03-24       Impact factor: 1.618

Review 3.  Current status of in vivo bioanalysis of nano drug delivery systems.

Authors:  Tingting Wang; Di Zhang; Dong Sun; Jingkai Gu
Journal:  J Pharm Anal       Date:  2020-05-16

Review 4.  Silica-Based Monolithic Columns as a Tool in HPLC-An Overview of Application in Analysis of Active Compounds in Biological Samples.

Authors:  Michał Staniak; Magdalena Wójciak; Ireneusz Sowa; Katarzyna Tyszczuk-Rotko; Maciej Strzemski; Sławomir Dresler; Wojciech Myśliński
Journal:  Molecules       Date:  2020-07-09       Impact factor: 4.411

5.  The availability of drug by liposomal drug delivery : Individual kinetics and tissue distribution of encapsulated and released drug in mice after administration of PEGylated liposomal prednisolone phosphate.

Authors:  Evelien A W Smits; José A Soetekouw; Ebel H E Pieters; Coen J P Smits; Nicolette de Wijs-Rot; Herman Vromans
Journal:  Invest New Drugs       Date:  2018-12-13       Impact factor: 3.850

Review 6.  Mapping of the available standards against the regulatory needs for nanomedicines.

Authors:  Blanka Halamoda-Kenzaoui; Uwe Holzwarth; Gert Roebben; Alessia Bogni; Susanne Bremer-Hoffmann
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-06-20

7.  Development of a method to quantify total and free irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation.

Authors:  Wenqian Yang; Zimeng Yang; Jieru Liu; Dan Liu; Yongjun Wang
Journal:  Asian J Pharm Sci       Date:  2018-09-11       Impact factor: 6.598

8.  Sensitive LC-MS/MS Methods for Amphotericin B Analysis in Cerebrospinal Fluid, Plasma, Plasma Ultrafiltrate, and Urine: Application to Clinical Pharmacokinetics.

Authors:  Leandro Francisco Pippa; Maria Paula Marques; Anna Christina Tojal da Silva; Fernando Crivelenti Vilar; Tissiana Marques de Haes; Benedito Antônio Lopes da Fonseca; Roberto Martinez; Eduardo Barbosa Coelho; Lauro Wichert-Ana; Vera Lucia Lanchote
Journal:  Front Chem       Date:  2021-11-29       Impact factor: 5.221

9.  Pharmacokinetics of a liposomal formulation of doxorubicin in rats.

Authors:  Zongyu Liu; Ye Bi; Yating Sun; Fei Hao; Jiahui Lu; Qingfan Meng; Robert J Lee; Yaping Tian; Jing Xie
Journal:  Saudi Pharm J       Date:  2017-05-13       Impact factor: 4.330

Review 10.  Analytical methods for investigating in vivo fate of nanoliposomes: A review.

Authors:  Chong Su; Yingze Liu; Yang He; Jingkai Gu
Journal:  J Pharm Anal       Date:  2018-07-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.